Medical Supplies Stock Performance Review -- Tandem Diabetes Care, Ekso Bionics, OraSure Technologies, and Hill-Rom

Wednesday, October 18, 2017 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 18, 2017 /PRNewswire/ --

If you want a Stock Review on TNDM, EKSO, OSUR, or HRC then come over

to and sign up for your free customized report. The Medical Instruments and Supplies Manufacturing industry primarily researches, develops, and produces non-electronic medical, surgical, dental, and veterinary
instruments and apparatus such as syringes, anesthesia apparatus, and blood transfusion equipment. This morning, recalls the previous performance of Tandem Diabetes Care Inc. (NASDAQ: TNDM), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), OraSure Technologies Inc. (NASDAQ: OSUR), and Hill-Rom Holdings Inc. (NYSE: HRC). These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Tandem Diabetes Care 

San Diego, California headquartered Tandem Diabetes Care Inc.'s stock finished Tuesday's session 3.12% lower at $2.48. A total volume of 1.09 million shares was traded, which was above their three months average volume of 221,230 shares. The Company's shares are trading below their 50-day moving average by 60.80%. Moreover, shares of Tandem Diabetes, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have a Relative Strength Index (RSI) of 29.24.

On October 16th, 2017, Tandem Diabetes Care announced plans to release its Q3 2017 results after the financial markets close on October 26th, 2017. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 p.m. ET to discuss its financial and operating results. Your complete research report on TNDM can be retrieved for free at

Ekso Bionics Holdings 

Shares in Richmond, California headquartered Ekso Bionics Holdings Inc. plummeted 5.98%, ending yesterday's session at $1.10. A total volume of 769,811 shares was traded, which was above their three months average volume of 498,700 shares. The stock is trading 16.06% below its 50-day moving average. Moreover, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, Middle-East, and Africa, have an RSI of 35.86.  

On September 22nd, 2017, Ekso Bionics announced the appointment of Ted Wang, PhD. to its Board of Directors, effective immediately. Dr. Wang is the Chief Investment Officer of Puissance Capital Management, a global asset manager founded in 2015 with offices in the US and China.  A free report on EKSO is just a click away at:

OraSure Technologies 

On Tuesday, Bethlehem, Pennsylvania-based OraSure Technologies Inc.'s stock saw a correction of 9.92%, to close the day at $18.89. A total volume of 3.28 million shares was traded, which was above their three months average volume of 691,510 shares. The Company's shares have advanced 1.78% in the previous three months and 115.15% on an YTD basis. The stock is trading 23.14% above its 200-day moving average. Additionally, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have an RSI of 22.96.  

On October 11th, 2017, OraSure Technologies announced that it has scheduled its regular earnings conference call covering Q3 2017 financial results, Q4 2017 financial guidance, and certain business developments on November 01st, 2017, at 5:00 p.m. ET. The conference call will be webcast live and may be accessed under the Investor Relations page of the Company's website. Sign up for your complimentary research report on OSUR at:

Hill-Rom Holdings 

Shares in Chicago, Illinois headquartered Hill-Rom Holdings Inc. ended the day 0.96% higher at $78.72. A total volume of 456,820 shares was traded. The stock has gained 4.71% in the last one month and 40.22% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.43% and 8.88%, respectively. Furthermore, shares of Hill-Rom, which operates as a medical technology company worldwide, have an RSI of 63.80.  

On September 28th, 2017, Hill-Rom announced that it will host its Q4 FY17 earnings conference call and webcast on November 03rd, 2017, beginning at 8:00 a.m. EDT and ending at approximately 9:30 a.m. EDT. A simultaneous webcast of the call will be accessible via the Company's website.  Register for free on and download the latest research report on HRC at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store